Actively Recruiting
Phase II Trial of Lutetium-177 PSMA with Stereotactic Ablative Radiotherapy for Men with Oligometastatic Prostate Cancer
Led by Peter MacCallum Cancer Centre, Australia · Updated on 2025-07-11
92
Participants Needed
3
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying oligometastatic prostate cancer, which means prostate cancer that has spread to a few sites in the body. The study aims to compare the progression-free survival of patients treated with stereotactic ablative body radiotherapy SABR alone versus SABR combined with a radioactive drug called Lutetium-177 prostate-specific membrane antigen 177Lu-PSMA. This trial is a randomized Phase II study focusing on men with a limited number of metastatic sites identified using advanced PSMA PET imaging. Participants will be randomly assigned to one of two groups. One group will receive 1 to 3 sessions of SABR focused on all cancer sites. The other group will receive the same SABR treatment plus two cycles of the 177Lu-PSMA radiopharmaceutical, administered between the SABR sessions over 24 months. The 177Lu-PSMA treatment targets cancer cells with a radioactive particle to help control disease progression. During the study, 92 men will be closely monitored with imaging scans, blood tests, and quality of life questionnaires. Researchers will track the progression-free survival up to 12 months after the last patient begins treatment, as well as other outcomes like side effects, survival rates, and healthcare costs. The study includes regular assessments of prostate-specific antigen PSA levels and patterns of cancer recurrence using PSMA PET scans, with follow-up visits over an average of three years.
CONDITIONS
Brief Title
Lu-PSMA for Oligometastatic Prostate Cancer Treated With STereotactic Ablative Radiotherapy
Research Team
G
Gaurav Sharma
A
Annette VanDerHeyden
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here